** Shares of gene therapy maker bluebird bio BLUE.O fall 38.6% to $4.32 premarket
** Co says it would be taken private by Carlyle CG.O and SK Capital Partners
** BLUE stockholders will receive $3/shr in cash, implying an equity value of around $29.2 mln
** The offer is at an over 57% discount from the stock's last close of $7.04
** Investment firms have also offered additional $6.84/shr, contingent upon achieving certain sales milestones, which represents a payment of about $66.5 mln
** BLUE fell 69.8% in 2024
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。